Intervention
Ozone Therapy
Ozone Therapy (Oxygen-Ozone Therapy)
Medical and alternative therapy using ozone gas (O3) for proposed anti-inflammatory, antimicrobial, and oxygenation benefits. Evidence base is mixed and safety concerns exist.
Summary Can ozone therapy slow aging or improve health? Show / hide ↓
Ozone therapy puts ozone gas into the body through methods such as treated blood, injections, rectal use, or skin applications. Supporters claim it may reduce inflammation, kill microbes, and improve oxygen delivery by causing a controlled form of cell stress. Research is limited and mixed: some studies suggest possible benefits for herniated discs and skin ulcers, while evidence for fibromyalgia mainly concerns safety. No studies have shown that ozone therapy extends life or slows aging. Ozone can damage the lungs if inhaled, and other risks include infection, blood-cell damage, and uncertain side effects; it is not approved by the FDA.
What this means for you: There is not enough evidence to use ozone therapy for longevity or anti-aging. It also carries real safety risks, so claims made by clinics should be viewed cautiously.
conflicting evidenceWhat it is
Ozone therapy involves administering ozone gas (O3) into the body via various routes: autohaemotherapy (blood is withdrawn, mixed with ozone, and reinfused), rectal insufflation, local injection, or topical application. Ozone is an unstable, reactive gas that rapidly decomposes, creating a controlled oxidative stress.
How it works
The proposed mechanism is controlled oxidative stress. When ozone contacts blood or tissues, it decomposes into oxygen and reactive oxygen species. This is proposed to stimulate endogenous antioxidant defenses (via the Nrf2 pathway), improve oxygen delivery to tissues, and have antimicrobial effects. Whether the controlled oxidative stress produces net benefit or harm in specific clinical contexts is debated.
Evidence
A 2026 umbrella review of systematic reviews with meta-analyses of RCTs (Cacciatore et al., Med Sci, June 2026) assessed the overall evidence base. Some evidence exists for specific conditions: herniated discs (RCT in Eur Spine J, April 2026), skin ulcers (review in Med Gas Res, 2026), and fibromyalgia (safety scoping review in Clin Exp Rheumatol, June 2026). No trials exist for longevity, anti-aging, or lifespan outcomes.
Safety concerns
Ozone is a toxic gas. The FDA has stated that ozone has no known useful medical application as a drug, and that inhaling ozone can cause lung damage, chest pain, coughing, shortness of breath, and throat irritation. Autohaemotherapy carries risk of infection if equipment is not properly sterilized. Ozone therapy is contraindicated in G6PD deficiency (risk of hemolysis), pregnancy, severe hyperthyroidism, and bleeding disorders. The safety profile is incompletely characterized, and adverse event reporting is inconsistent.
What to know
Ozone therapy sits firmly in the alternative medicine space. It is available at clinics in some countries (Germany, Italy, Russia) and at alternative medicine clinics in the US. The evidence base, while growing with the 2026 umbrella review, does not support longevity claims. The treatment carries real safety risks. Anyone considering ozone therapy should be aware that it is not FDA-approved, the FDA has explicitly stated ozone has no known useful medical application, and safety monitoring varies widely between practitioners.
A September 2026 critical appraisal in Frontiers in Medicine graded the clinical ozone evidence across fields. For knee osteoarthritis, an umbrella review found every included systematic review rated critically low quality on AMSTAR-2. Dental-caries evidence was very low certainty with no clinical recommendation possible. Dermatology evidence was preliminary and methodologically inconsistent. The strongest signal remains lumbar disc herniation: a meta-analysis of 12 studies covering roughly 8,000 patients found percutaneous ozone injection improved pain and Oswestry Disability Index scores comparably to surgical discectomy, with a complication rate of 0.064%. The appraisal concluded evidence quality, not procedure availability, is the limiting factor for clinical ozone use.
Further reading
Curated external sources for a deeper dive. External links open in a new tab.